Drug-eluting balloon versus bare-mental stent and drug-eluting stent for de novo coronary artery disease: A systematic review and meta-analysis of 14 randomized controlled trials

Kongyong Cui, Shuzheng Lyu*, Xiantao Song, Fei Yuan, Feng Xu, Min Zhang, Wei Wang, Dongfeng Zhang, Jing Dai

Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University and Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China

* shuzheng@medmail.com.cn

Abstract

Background
Drug-eluting balloon (DEB) has become an alternative option to drug-eluting stent (DES) for the treatment of in-stent restenosis (ISR). However, the effect of drug-eluting balloon with regular bare-mental stent (BMS) in de novo coronary artery disease (CAD) is unclear. This meta-analysis aimed to evaluate the efficacy of DEB with regular BMS compared to BMS or DES in de novo CAD.

Methods
Randomized controlled trials (RCTs) assessing the efficacy of DEB+BMS in comparison with BMS or DES were obtained by searching the PubMed, EMBASE, and Cochrane Library databases through January 2016. Primary endpoints were major adverse cardiac events (MACEs) and late lumen loss (LLL). Secondary endpoints included death, myocardial infarction (MI), target lesion revascularization (TLR), stent thrombosis (ST), binary restenosis, and minimum lumen diameter (MLD). Dichotomous and continuous data were presented as odds ratios (ORs) and mean differences (MDs) with 95% confidence intervals (CIs), respectively, and analyzed using a random-effects model.

Results
A total of 14 RCTs involving 2281 patients were included in this meta-analysis. DEB+BMS showed significantly less MACEs (OR: 0.67, 95%CI 0.45 to 0.99, P = 0.04) and reduced LLL (MD: -0.30 mm, 95%CI: -0.48 mm to -0.11 mm, P = 0.001) compared with BMS. Meanwhile, treatment with DEB+BMS had disadvantages over DES in terms of MACEs (OR: 1.94, 95% CI 1.24 to 3.05, P = 0.004), LLL (MD: 0.20 mm, 95%CI: 0.07 mm to 0.33 mm, P = 0.003), TLR (OR: 2.53, 95% CI 1.36 to 4.72, P = 0.003), and MLD (MD: -0.25 mm, 95%CI: -0.42 mm to -0.09 mm, P = 0.003).
Conclusions

This limited evidence demonstrated that treatment with DEB+BMS appears to be effective in de novo CAD. In addition, DEB+BMS clearly showed superiority to BMS, but is inferior to DES in the treatment of patients with de novo CAD. Hence, DES (especially new generation DES) should be recommended for patients with de novo CAD.

Introduction

First-generation drug-eluting stents (DESs) reduce restenosis after percutaneous coronary intervention (PCI) by preventing vessel wall recoil and late negative remodeling, as well as restraining neointimal hyperplasia [1,2]. However, they are associated with many potential serious complications such as late stent thrombosis, non-homogenous drug delivery, and delayed vascularization, which makes bare-mental stent (BMS) preferred with shorter dual antiplatelet therapy in patients at high bleeding risk [3,4]. Recently, network meta-analyses has demonstrated new generation DES was associated with significantly lower rates of stent thrombosis in comparison to BMS [5,6]. Furthermore, randomized controlled trials (RCTs) with new generation DES have shown lower rate of stent thrombosis and similar risk of bleeding compared with BMS in patients with contraindications to first-generation DES [7,8]. Obviously, new generation DES might be an appropriate choice for the treatment of de novo coronary disease among patients at high risk of bleeding or thrombosis.

Local drug delivery by drug-eluting balloon (DEB) has emerged as an effective and safe treatment option for in-stent restenosis (ISR) in both BMS [9] and DES [10,11], delivering active drugs homogeneously to inhibit neointimal hyperplasia without remaining in the arteries permanently. To date, DEB is considered an important method for treating BMS-ISR and DES-ISR in the updated European Society of Cardiology guidelines with a class I recommendation (level of evidence A) [12]. Furthermore, DEB can also deliver drugs to de novo coronary lesions. Indeed, it is usually used in combination with BMS, especially for lesions without local flow-limiting vessel dissections and high-grade elastic recoil. Although previous meta-analyses demonstrated that DEB+BMS was not superior to BMS, while DEB with/without BMS tended to be inferior to DES without statistical differences, the effect of DEB with regular BMS compared with BMS or DES in de novo coronary artery disease (CAD) remains unclear and the topic is challenging till now [13,14]. Firstly, the studies were restricted to small sample size [13,14]. In fact, DEB was not widespread for de novo coronary lesions due to lack of recommendation in contemporary guidelines and the development of new generation DES and bioresorbable stent. Secondly, studies that applied both DEB alone and DEB with regular BMS were included in previous meta-analyses, which may cause severe heterogeneity [13,14]. Thirdly, first-generation DES was used in most of the studies, whereas DEB should compare with current standard of new generation DES with the development of stent design. Recently, several RCTs using DEB+BMS to treat de novo lesions comparatively with BMS or DES treatments were reported. Importantly, new generation DES was widely adapted in these studies. We performed an updated meta-analysis of all currently available RCTs to evaluate DEB+BMS efficacy in the treatment of de novo CAD.
Methods

This study was carried out in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [15].

Search strategy

RCTs investigating the efficacy of DEB+BMS comparatively to BMS or DES in de novo CAD were included. Pertinent articles were identified through a comprehensive search of electronic databases, including PubMed, EMBASE, and Cochrane Library through January 2016. Only studies published in English and limited to human subjects were taken into account. The following medical subject headings and search terms were used: “drug eluting balloon”, “drug coated balloon”, “paclitaxel coated balloon”, and “paclitaxel eluting balloon”. The references in the identified articles and relevant reviews were screened to include other potentially suitable trials. The authors of the original studies were not contacted for additional information.

Study selection

Studies were included if they: (1) were RCTs associated with de novo CAD; (2) were published in English and limited to human subjects; (3) compared DEB+BMS to BMS or DES; (4) had subjects followed for at least 6 months; (5) assessed the endpoints of interest. At first, the selection was conducted by screening titles or abstracts; then, full-text reviews were performed. When several reports overlapped, only the largest and latest one was selected. All articles were reviewed by two independent investigators (WW and JD) to determine whether they met the inclusion criteria, and any disagreement was resolved by consensus.

Data extraction

The following data were extracted using a standardized form for each eligible article: study characteristics, patient characteristics, and angiographic and clinical outcomes. Primary endpoints were major adverse cardiac events (MACEs) and late lumen loss (LLL). MACEs were defined as a composite of death, MI, and TLR, while the definition of LLL was the difference between the postprocedural and follow-up minimum lumen diameter (MLD) in the same segment. The most similar endpoint was chosen in case one endpoint was not reported. Definitions of MACEs in the individual studies are shown in Table 1. Secondary endpoints included death, myocardial infarction (MI), target lesion revascularization (TLR, defined as any repeat revascularization in the treated segment), stent thrombosis (ST, classified according to the Academic Research Consortium definition [16]), binary restenosis (BR, defined as >50% of diameter stenosis), and MLD. Data extraction was performed by two independent investigators (FX and MZ), and differences in assessments were resolved by discussing with a third investigator (FY).

Quality assessment

The quality of eligible articles was assessed by evaluating the following methodological criteria recommended by the Cochrane Collaboration: sequence generation, concealment of allocation, blinding, incomplete outcome data, selective outcome reporting, and other sources of bias [17].

Statistical analysis

All statistical analyses were carried out with Review Manager 5.1 (Cochrane Center, Denmark). Dichotomous data were presented as odds ratios (ORs) with 95% confidence intervals.
| Study | Author Year | Study Design | Patient characteristics | Comparison | Total no. patients | DEB/ BMS (n) | DES (n) | Other (n) | Clinical f/u (mts) | Angiographic f/u (mts) | MACE | Death, MI, TVR |
|-------|-------------|--------------|--------------------------|------------|--------------------|-------------|---------|-----------|------------------|----------------------|-------|---------------|
| Ali 2011 | [18] | Single center | SA or UA with diabetes mellitus; single de novo stenosis | SeQuent Please DEB+BMS vs. Taxus Liberte PES | 84 45 NA 39 | DEB+BMS 3, DES 6 | 117 40 37 40 | 84 45 NA 39 | 9 9 | 6 6 6 6 | 6 6 6 6 |
| Belkacemi 2011 | [19,33] | Multicenter | SA or UA; bifurcation | DIOR-I DEB+BMS vs. BMS vs. Taxus Liberte PES | 117 40 37 40 | DEB+BMS 3, DES 6 | 117 40 37 40 | 117 40 37 40 | 6 6 6 6 | 6 6 6 6 | 6 6 6 6 |
| Belkacemi 2012 | [20] | Multicenter | STEMI; a single culprit lesion in the target vessel | DIOR-II DEB+BMS vs. BMS vs. Taxus Liberte PES | 150 50 51 49 12 6 6 | DEB+BMS 3, DES 6 | 150 50 51 49 12 6 6 | 150 50 51 49 12 6 6 | 9 9 | 9 9 | 9 9 |
| Besic 2015 | [21] | Single-center | NSTEMI or UA; de novo coronary lesions | Elutax/SeQuent Please DEB+BMS vs. BMS | 85 41 44 NA 12 6 6 | DEB+BMS 3, DES 6 | 85 41 44 NA 12 6 6 | 85 41 44 NA 12 6 6 | 9 9 | 9 9 | 9 9 |
| Burzotta 2015 | [22] | NA | SA, non-diabetic, single de novo coronary lesions | IN.PACT Falcon DEB+BMS vs. BMS | 30 20 10 NA 3 | DEB+BMS 3, DES 6 | 30 20 10 NA 3 | 30 20 10 NA 3 | 9 9 | 9 9 | 9 9 |
| Camano 2015 | [23] | NA | SA or UA; single de novo stenosis | Cordis DEBlue DEB+BMS vs. BMS | 108 52 NA 56 | DEB+BMS 3, DES 6 | 108 52 NA 56 | 108 52 NA 56 | 9 9 | 9 9 | 9 9 |
| Hamm 2009 | [24] | NA | SA or UA; single de novo coronary lesions | Cordis DEBlue DEB+BMS vs. BMS | 90 51 NA 48 12 | DEB+BMS 3, DES 6 | 90 51 NA 48 12 | 90 51 NA 48 12 | 9 9 | 9 9 | 9 9 |
| Lisboa 2010 | [25] | NA | SA or UA; single de novo coronary lesions | ExtraMed BMS vs. Xience V EES | 637 312 325 12 | DEB+BMS 3, DES 6 | 637 312 325 12 | 637 312 325 12 | 9 9 | 9 9 | 9 9 |
| Lopez 2010 | [26] | NA | SA or UA; single de novo coronary lesions | ExtraMed BMS vs. Xience V EES | 126 59 NA 66 | DEB+BMS 3, DES 6 | 126 59 NA 66 | 126 59 NA 66 | 9 9 | 9 9 | 9 9 |
| Poerner 2014 | [27] | NA | SA or UA; single de novo coronary lesions | SeQuent Please DEB+BMS vs. Xience V EES | 223 111 112 NA | DEB+BMS 3, DES 6 | 223 111 112 NA | 223 111 112 NA | 9 9 | 9 9 | 9 9 |
| Seeger 2016 | [28] | NA | SA or UA; single de novo coronary lesions | No significant differences between DEB+BMS vs. BMS | 120 62 58 NA 3 | DEB+BMS 3, DES 6 | 120 62 58 NA 3 | 120 62 58 NA 3 | 9 9 | 9 9 | 9 9 |
| Seeger 2016 | [29] | NA | SA or UA; single de novo coronary lesions | No significant differences between DEB+BMS vs. BMS | 90 51 NA 48 12 | DEB+BMS 3, DES 6 | 90 51 NA 48 12 | 90 51 NA 48 12 | 9 9 | 9 9 | 9 9 |
| Touchard 2015 | [30] | NA | SA or UA; single de novo coronary lesions | SeQuent Please DEB+BMS vs. Xience V EES | 180 90 NA 90 | DEB+BMS 3, DES 6 | 180 90 NA 90 | 180 90 NA 90 | 9 9 | 9 9 | 9 9 |
| Yoon 2015 | [31] | NA | SA; non-diabetic, single de novo coronary lesions | No significant differences between DEB+BMS vs. BMS | 223 111 112 NA | DEB+BMS 3, DES 6 | 223 111 112 NA | 223 111 112 NA | 9 9 | 9 9 | 9 9 |

**Table 1. Study and population characteristics.**

- **Primary author, year published:** The authors and the year of publication for each study.
- **Study characteristics:** The study design, patient characteristics, and comparison groups.
- **Total no. patients:** The total number of patients in each study.
- **DEB/BMS (n):** The number of patients in the drug-eluting balloon (DEB) and bare-metal stent (BMS) groups.
- **DES (n):** The number of patients in the drug-eluting stent (DES) group.
- **Other (n):** The number of patients in any other relevant groups.
- **Clinical f/u (mts):** The number of months of clinical follow-up.
- **Angiographic f/u (mts):** The number of months of angiographic follow-up.
- **MACE:** Major adverse cardiac events.
- **Death, MI, TVR:** Death, myocardial infarction, and target vessel revascularization.
- **No. of FU, follow-up; mts, months; NA, not applicable; DEB, drug-eluting balloon; BMS, bare-metal stent; EPC, endothelial progenitor cell capturing; DES, drug-eluting stent; PES, paclitaxel-eluting stent; SES, sirolimus-eluting stent; EES, everolimus-eluting stent; ZES, zotarolimus-eluting stent; MACE, major adverse cardiac events; TLR, target lesion revascularization; TVR, target vessel revascularization; ST, stent thrombosis; CAD, coronary artery disease; SA, stable angina; UA, unstable angina; MI, myocardial infarction; NSTEMI, non ST-segment elevation myocardial infarction; ACS, acute coronary syndrome.**

* 9 patients with >1 suitable lesion were sequentially included in both device groups.*
(CIs): these included MACEs, death, MI, TLR, ST and BR. A quantitative analysis was performed to estimate the mean differences (MDs) for continuous variables with 95% CI. Potential heterogeneity among trials was assessed with the I² statistical test. An I² value exceeding 50% was defined as statistical heterogeneity. For ORs, the Dersimonian and Lair random-effects model was used, while the overall mean difference was constructed with the Inverse Variance random-effects model.

Sensitivity analyses were performed to demonstrate the robustness of results by removing studies according to the conditions described below. For DEB+BMS vs. BMS: (1) excluding endothelial progenitor cell capturing (EPC) stent; (2) excluding ST-segment elevation myocardial infarction (STEMI); (3) excluding bifurcations. In the case of DEB+BMS vs. DES: (1) excluding STEMI; (2) excluding bifurcations; (3) SeQuent Please exclusively; (4) paclitaxel-eluting stent (PES) exclusively; (5) everolimus-eluting stent (EES) exclusively; (6) published in full text exclusively. Sensitivity analyses were also performed by omitting one study in each turn. Two-sided P values <0.05 were considered statistically significant.

Results

Eligible studies

After a comprehensive review of the retrieved articles, 1594 potentially related reports were identified in the initial analysis. A total of 521 articles were removed due to duplication and 1041 excluded after initial screening based on title and/or abstract. A total of 32 articles were selected for complete review. Finally, 14 RCTs [18,19,20,21,22,23,24,25,26,27,28,29,30,31] involving 2281 patients were included in the current meta-analysis. The study selection process is summarized in Fig 1. In the OCTOPUS study, 24 month clinical outcomes were reported as an abstract [32], with data not yet available; therefore the related study with six-month angiographic and clinical follow up data was enrolled [27].

Study and population characteristics are presented in Table 1. Of the 14 RCTs, 7 compared DEB+BMS and DES [18,24,25,26,27,30,31]; meanwhile, 5 trials compared DEB+BMS and BMS [21,22,23,28,29], and the remaining 2 were 3-arm trials comparing DEB+BMS, BMS, and DES [19,20]. The DEBs used in original trials were SeQuent Please [18,26,27,28,30,31], Dior [19,20], IN.PACT Falcon [22], and other paclitaxel-eluting balloons. One study [21] used two DEB types, including SeQuent Please and Elutax. The devices used in control arms were BMS (7 arms) and DES (9 arms); regarding the type of DES, PES (4 arms), EES (3 arms), zotarolimus-eluting stent (ZES) (1 arm) and sirolimus-eluting stent (SES) (1 arm) were included. Overall, 3 trials enrolled patients with STEMI [20,23,29]; in the remaining 11 trials, patients with stable angina, unstable angina or non-ST segment elevation myocardial infarction were enrolled. Concerning lesion subsets, bifurcations [19,26] and simple de novo lesions [18,20,21,22,23,24,25,27,28,29,30,31] were all included in this meta-analysis. Clinical follow-up period ranged from 6 to 60 months; the duration of angiographic follow-up varied between 6 and 9 months. Quality assessment results are detailed in Table 2.

Primary endpoints

Major adverse cardiac events. Overall, MACEs were reported in 13 studies (28 arms). MACEs occurred in 170 (16.9%), 76 (20.4%) and 73 (10.1%) patients in the DEB+BMS, BMS and DES groups, respectively. The pooled OR for MACEs is shown in Fig 2A and 2B. Compared with the BMS group, treatment with DEB+BMS was associated with a lower risk of MACEs (OR: 0.67, 95%CI 0.45 to 0.99, P = 0.04, I² = 0%) (Fig 2A). In contrast, the risk of MACEs was significantly reduced in the DES group compared with DEB+BMS treated patients (OR: 1.94, 95%CI 1.24 to 3.05, P = 0.004, I² = 34%) (Fig 2B).
Late lumen loss. As shown in Fig 3A and 3B, LLL data were available in 12 trials (26 arms). Compared with the BMS group, treatment with DEB+BMS was associated with reduced LLL (MD: -0.30 mm, 95%CI: -0.48 mm to -0.11 mm, P = 0.001, I² = 67%) (Fig 3A); meanwhile, the DEB+BMS group was inferior to the DES group in terms of LLL (MD: 0.20 mm, 95%CI: 0.07 mm to 0.33 mm, P = 0.003, I² = 76%) (Fig 3B).

Secondary outcomes

Death. The rate of death was not significantly different for DEB+BMS vs. BMS (OR: 1.13, 95% CI 0.41 to 3.09, P = 0.81, I² = 0%) and DEB+BMS vs. DES (OR: 2.14, 95% CI 0.51 to 9.00, P = 0.30, I² = 0%), respectively (Table 3).
Table 2. Assessment of randomized controlled trials.

| Primary author, year published | Sequence generation | Concealment of allocation | blinding of participants, personnel and outcome assessors | Incomplete outcome data addressed | Free of selective reporting | Free of other bias |
|-------------------------------|---------------------|---------------------------|----------------------------------------------------------|----------------------------------|---------------------------|------------------|
| Ali 2011[18]                  | NA                  | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |
| Belkacemi 2011[19,33]         | Yes                 | Yes                       | Yes                                                      | Yes                              | Yes                       | Yes              |
| Belkacemi 2012[20]           | Yes                 | Yes                       | Yes                                                      | Yes                              | Yes                       | Yes              |
| Besic 2015[21]                | NA                  | NA                        | NA                                                       | Yes                              | Yes                       | Yes              |
| Burzotta 2015[22]            | NA                  | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |
| Camaro 2015[23]              | NA                  | NA                        | NA                                                       | NA                               | NA                       | NA               |
| Hamm 2009[24,34]              | NA                  | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |
| Liistro 2013[25]              | Yes                 | Yes                       | Yes                                                      | Yes                              | Yes                       | Yes              |
| Lopez 2014[26]               | Yes                 | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |
| Poerner 2014[27]             | NA                  | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |
| Seeger 2016[28]              | Yes                 | Yes                       | Yes                                                      | Yes                              | Yes                       | Yes              |
| Touchard 2015[29]            | NA                  | NA                        | NA                                                       | NA                               | NA                       | NA               |
| Yoon 2015[30]                | NA                  | NA                        | NA                                                       | NA                               | NA                       | NA               |
| Zurakowski 2015[31]           | Yes                 | NA                        | Yes                                                      | Yes                              | Yes                       | Yes              |

NA, not applicable;

https://doi.org/10.1371/journal.pone.0176365.t002

Fig 2. Forest plot of major adverse cardiac events comparing DEB+BMS with (A) BMS and (B) DES.

https://doi.org/10.1371/journal.pone.0176365.g002
Table 3. Secondary endpoints.

| Outcomes | Comparison         | No. Trials | No. patients (or lesions)* | OR/MD (95% CI) | P value | I², % |
|----------|--------------------|------------|---------------------------|----------------|---------|------|
| Death    | DEB+BMS vs. BMS    | 5          | 211/198                   | 1.13[0.41, 3.09] | 0.81    | 0%   |
|          | DEB+BMS vs. DES    | 8          | 489/490                   | 2.14[0.51, 9.00] | 0.30    | 0%   |
| MI       | DEB+BMS vs. BMS    | 4          | 170/154                   | 2.12[0.62, 7.26] | 0.23    | 0%   |
|          | DEB+BMS vs. DES    | 8          | 489/490                   | 1.19[0.47, 3.04] | 0.72    | 0%   |
| TLR      | DEB+BMS vs. BMS    | 6          | 322/310                   | 0.69[0.43, 1.10] | 0.12    | 0%   |
|          | DEB+BMS vs. DES    | 8          | 699/715                   | 2.53[1.36, 4.72] | 0.003   | 38%  |
| ST       | DEB+BMS vs. BMS    | 5          | 302/300                   | 2.06[0.42, 10.11] | 0.37    | 0%   |
|          | DEB+BMS vs. DES    | 4          | 237/228                   | 1.27[0.41, 3.98] | 0.68    | 0%   |
| BR       | DEB+BMS vs. BMS    | 4          | 227/233                   | 0.47[0.12, 1.84] | 0.26    | 83%  |
|          | DEB+BMS vs. DES    | 7          | 322/323                   | 2.26[1.01, 5.08] | 0.05    | 58%  |
| MLD(mm)  | DEB+BMS vs. BMS    | 4          | 133/129                   | 0.08[-0.11, 0.26] | 0.42    | 0%   |
|          | DEB+BMS vs. DES    | 6          | 274/274                   | -0.25[-0.42, -0.09] | 0.003   | 64%  |

MI, myocardial infarction; TLR, target lesion revascularization; ST, stent thrombosis; BR, binary restenosis; MLD, minimal lumen diameter; DEB, drug-eluting balloon; BMS, bare-mental stent; DES, drug-eluting stent; NO., number of; OR, odd ratio; MD, mean difference; CI, confidence internal;

*The numerals indicate the number of cases and controls, respectively.

https://doi.org/10.1371/journal.pone.0176365.t003

Fig 3. Forest plot of late lumen loss comparing DEB+BMS with (A) BMS and (B) DES.

https://doi.org/10.1371/journal.pone.0176365.g003
Myocardial infarction. Overall, no statistically significant differences in MI were obtained between DEB+BMS and BMS (OR: 2.12, 95% CI 0.62 to 7.26, P = 0.23, I² = 0%) or DEB+BMS and DES (OR: 1.19, 95% CI 0.47 to 3.04, P = 0.72, I² = 0%) groups (Table 3).

Target lesion revascularization. A total of 12 trials (26 arms) reported target lesion revascularization. As shown in Table 3, pooled OR for TLR was similar between the DEB+BMS and BMS groups (OR: 0.69, 95% CI 0.43 to 1.10, P = 0.12, I² = 0%). Nevertheless, DEB+BMS treatment was associated with a higher rate of TLR compared with the DES group (OR: 2.53, 95% CI 1.36 to 4.72, P = 0.003, I² = 38%).

Stent thrombosis. The incidence of stent thrombosis was low in both groups. In the pooled estimate, the risk of stent thrombosis was similar between DEB+BMS and BMS groups (OR: 2.06, 95% CI 0.42 to 10.11, P = 0.37, I² = 0%) or DEB+BMS and DES groups (OR: 1.27, 95% CI 0.41 to 3.98, P = 0.68, I² = 0%) (Table 3).

Binary restenosis. Binary restenosis was reported in 9 trials (20 arms) by angiographic follow-up. As shown in Table 3, no significant differences were observed between DEB+BMS and BMS groups (OR: 0.47, 95% CI 0.12 to 1.84, P = 0.28, I² = 83%). Treatment with DEB+BMS tended to be superior to DES in terms of binary restenosis (OR: 2.26, 95% CI 1.01 to 5.08, P = 0.05, I² = 58%).

Minimum lumen diameter. Overall, 8 studies including 18 arms reported minimum lumen diameter data. The pooled MDs for MLD are shown in Table 3. MLD was similar between DEB+BMS and BMS groups (MD: 0.08 mm, 95% CI: -0.11 mm to 0.26 mm, P = 0.42, I² = 0%). However, treatment with DEB+BMS was associated with reduced MLD compared with the DES group (MD: -0.25 mm, 95% CI: -0.42 mm to -0.09 mm, P = 0.003, I² = 64%).

Sensitivity analysis. To assess the robustness of primary endpoint results, sensitivity analyses performed through removal of any single trial, which did not essentially affect the overall pooled estimate in the DEB+BMS vs. BMS and DEB+BMS vs. DES groups, respectively (data not shown).

Sensitivity analysis was also performed by evaluating the effects of various variables in the included trials (Table 4). Mostly similar results were obtained compared to the overall analysis. In the analysis comparing DEB+BMS to BMS, no statistical differences were found between the two groups after exclusion of patients with STEMI, although DEB+BMS was associated with a lower rate of MACEs (OR: 0.73, 95% CI 0.44 to 1.21, P = 0.23) and reduced LLL (MD: -0.19 mm, 95% CI: -0.41 mm to 0.03 mm, P = 0.09). On the other hand, comparing DEB+BMS to DES, analysis of trials using SeQuent Please showed that both groups were comparable in MACEs (OR: 0.98, 95% CI 0.49 to 1.94, P = 0.95) and LLL (MD: 0.10 mm, 95% CI: -0.04 to 0.23, P = 0.15). Furthermore, treatment with DEB+BMS was comparable to PES exclusively regarding MACEs (OR: 1.46, 95% CI 0.73 to 2.91, P = 0.29) and LLL (MD: 0.12 mm, 95% CI: -0.06 mm to 0.29 mm, P = 0.19).

Discussion

This present meta-analysis involving 2281 patients showed that DEB with regular BMS was effective in treating de novo coronary disease. Treatment with DEB+BMS was superior to BMS therapy in angiographic and clinical follow-up because DEB+BMS versus BMS showed significantly reduced MACE incidence and LLL. Meanwhile, treatment with DEB+BMS was inferior to DES that it was associated with negative results in terms of MACE, LLL, TLR, and MLD. Furthermore, treatment with DEB+BMS was comparable to PES while tended to be inferior to second-generation DES based on a small sample size in subset analysis.

First-generation DES is restricted to prolonged dual antiplatelet therapy compared with BMS, with increased risk of late stent thrombosis due to incomplete endothelialization of
Table 4. Sensitivity analyses.

| Outcome | DEB+BMS vs. BMS | DEB+BMS vs. DES |
|---------|-----------------|-----------------|
| MACE    | Excluding EPC stent | Excluding STEMI | Excluding bifurcation | Excluding STEMI | Excluding bifurcation | SeQuent Please exclusively | PES exclusively | EES exclusively | Published in full text exclusively |
|         | Including EPC stent | Including STEMI | Including bifurcation | Including STEMI | Including bifurcation | [0.49, 1.94] | [0.29] | [0.08] | [0.05] |
| MACE    | 0.64 [0.39, 1.03] | 0.73 [0.44, 1.21] | 1.80 [1.15, 2.82] | 1.96 [0.93, 3.55] | 0.98 [0.49, 1.94] | 1.16 [0.73, 1.91] | 2.60 [0.88, 7.66] | 2.04 [0.99, 4.20] | 0.07 |
| LLL (mm) | -0.26 [-0.51, -0.01] | -0.19 [-0.41, 0.03] | -0.33 [-0.52, 0.14] | 0.01 [0.40, 0.38] | 0.10 [-0.04, 0.23] | 0.12 [-0.06, 0.29] | 0.31 [-0.01, 0.63] | 0.19 [0.01, 0.36] | 0.04 |
| Death   | 0.71 [0.05, 0.79] | 1.40 [0.48, 4.05] | 0.87 [0.19, 3.91] | 0.14 [0.51, 0.90] | 2.01 [0.37, 10.83] | 2.01 [0.37, 10.83] | 4.60 [0.51, 41.38] | 4.90 [0.23, 104.7] | 0.11 |
| MI      | 3.95 [0.43, 36.5] | 1.77 [0.46, 6.81] | 0.01 [0.53, 7.64] | 1.02 [0.38, 2.74] | 1.26 [0.40, 3.98] | 1.26 [0.40, 3.98] | 1.41 [0.46, 4.35] | 0.80 [0.15, 4.37] | 0.70 |
| TLR     | 0.73 [0.43, 1.24] | 0.67 [0.38, 1.16] | 0.69 [0.41, 1.16] | 0.27 [1.24, 4.16] | 2.59 [1.15, 5.86] | 1.10 [0.33, 3.86] | 1.87 [0.43, 8.09] | 3.45 [0.88, 13.54] | 0.10 |
| ST      | 3.61 [0.61, 23.69] | 1.00 [0.10, 10.29] | 0.01 [0.42, 10.11] | 1.02 [0.30, 3.48] | 1.54 [0.46, 5.23] | 1.23 [0.33, 4.66] | 1.27 [0.41, 3.98] | NA | 1.54 [0.46, 5.23] |
| BR      | 0.47 [0.12, 1.84] | 0.75 [0.35, 1.60] | 0.08 [0.35, 2.66] | 1.88 [0.78, 4.49] | 2.20 [0.63, 7.66] | 0.75 [0.30, 1.84] | 1.50 [0.59, 3.88] | 5.23 [0.24, 134.42] | 0.08 |
| MLD (mm) | 0.08 [-0.11, 0.26] | 0.02 [-0.21, 0.25] | 0.02 [0.20, 0.33] | -0.21 [-0.39, -0.04] | -0.30 [-0.55, -0.05] | -0.11 [-0.25, 0.03] | -0.20 [-0.47, 0.07] | -0.30 [-0.56, -0.05] | 0.006 |

MACE, major adverse cardiac events; LLL, late lumen loss; OR, odds ratio; MD, mean difference; CI, confidence interval; NA, not applicable; DEB, drug-eluting balloon; BMS, bare-metal stent; EPC, endothelial progenitor cell capturing; DES, drug-eluting stent; PES, paclitaxel-eluting stent; LES, limus-eluting stent; STEMI, ST-segment elevation myocardial infarction

https://doi.org/10.1371/journal.pone.0176365.t004

stent struts and an inflammatory response to the polymeric coating [35]. With the development of stent materials, platforms, and delivery systems, second-generation DES has significantly improved safety and efficacy outcomes compared with BMS and first-generation DES [5,6]. LEADERS FREE trial has shown a polymer-free umirolimus-coated stent was superior to a BMS in terms of the safety endpoints composite of cardiac death, myocardial infarction, and definite or probable stent thrombosis with a 1-month course of dual antiplatelet therapy in patients at high risk for bleeding [7]. While ZEUS trial has demonstrated a lower risk of 1-year MACE (all-cause death, nonfatal MI, and any target vessel revascularization) without increasing risk of bleeding or thrombosis in patients with contraindications to old DES [8]. In fact, DEB can provide an immediate and homogenous drug uptake without stent struts or polymers [36,37,38]. DEB used in combination with BMS has the potential to inhibit neointimal hyperplasia without delayed vascularization, preventing acute vessel wall recoil [37]. Due to the absence of polymers and short presence of drugs in the vessel wall, the duration of dual antiplatelet therapy can be shortened.

Previous meta-analysis demonstrated that DEB+BMS appeared to be superior to BMS for de novo coronary lesions, with no significant difference [13,14]. Recently, several RCTs have assessed DEB+BMS for the treatment of de novo CAD compared to BMS. In the present meta-analysis, DEB+BMS showed an overt advantage over BMS in terms of MACEs and LLL. Both first-generation (PES and SES) and second-generation (EES and ZES) DES were adapted. Previous studies [13,14] indicated that DEB with/without BMS is comparable to DES for treating de novo CAD. In this analysis, only studies applying DEB with regular BMS were eligible.
because trials that used DEB alone with bail-out BMS were different in design, which can cause pronounced heterogeneity.

The PES consisted of stainless steel of 97 to 147 mm that elutes paclitaxel from a durable polymer, which is associated with medial necrosis, positive remodeling, and excessive fibrin deposition. Previous studies showed that second-generation DES, such as EES or ZES, have improved outcomes with respect to MACEs, ST, and MI compared with the PES [39,40]. Furthermore, SES could reduce TLR rate compared with PES in short term follow up [40]. Interestingly, EES, ZES, and SES elute drugs in the limus family that share the same underlying pharmacological mechanism [40].

In this study, we compared DEB+BMS with PES exclusively, and found no statistically significant difference between both groups in terms of angiographic and clinical endpoints (Table 4). The PEPCAD III trial [24] reported that SES is superior to DEB+BMS in terms of clinical outcomes. This multicenter randomized trial enrolled 637 patients with de-novo coronary artery lesions from 24 sites. In a 9-month clinical follow-up, DEB+BMS was shown to be associated with a higher risk of MACEs (P < 0.001) and TLR (P = 0.006). Obviously, this study obtained different results from reports comparing DEB+BMS and PES. In the current interventional practice, EES is the most common DES type used worldwide, in with the drug released from a biocompatible fluoro-copolymer coated onto a thinner cobalt—chromium stent [41]. Previous studies demonstrated that cobalt chromium EES is currently the most efficacious and safest device available for treating CAD [42,43]. The present meta-analysis only included three studies [25,26,27] comparing DEB+BMS with Xience V EES. Subset analysis showed that treatment with DEB+BMS tended to be inferior to Xience V EES in terms of MACEs (OR: 2.60, P = 0.08), LLL (MD: 0.31 mm, P = 0.06), TLR (OR: 3.45, P = 0.08), binary restenosis (OR: 5.23, P = 0.0006), and MLD (MD: -0.30 mm, P = 0.02). ZES is another second-generation DES, whose effectiveness has been confirmed [42]. A study conducted by Yoon et al. [30] enrolled patients with de novo non-small vessel CAD and compared DEB+BMS to Resolute Integrity ZES. With 180 patients randomly divided into DEB+BMS (n = 90) and ZES (n = 90) groups, the use of DEB+BMS was associated with disadvantageous outcomes compared to ZES regarding TLR (6.7% vs. 2.2%) and LLL (P < 0.001). Nonetheless, studies comparing DEB+BMS to new generation DES are scarce. More studies are needed to provide additional insights into the relative DEB efficacy in comparison with new generation DES.

Various types of DEB were assessed in the present analysis. We compared SeQuent Please in the treatment of de novo CAD with DES. Overall, SeQuent Please+ BMS was comparable to DES in terms of angiographic and clinical outcomes, indicating that SeQuent Please might be a promising alternative to DES in de novo CAD. However, these results cannot be extrapolated to DEBs in general. In the DEB-AMI study [20], Dior-II balloons were shown to be inferior to Taxus Liberté, both in angiographic and clinical outcomes at follow up. Indeed, Dior utilizes a peculiar coating technology, where adherence of paclitaxel is mediated by a roughened surface of the balloon, whereas in the SeQuent Please paclitaxel is stuck to a water-soluble matrix. Compared with SeQuent Please, Dior may have failed to warrant sufficient bioavailability of paclitaxel at the lesion site [19,20,44].

When DEB is used in combination with regular BMS, geographical mismatch between DEB-dilated segment and stent coverage is considered a potential problem, which leads to higher rates of restenosis, especially focal restenosis [45]. In the OCTOPUS study [27], BMS was systematically post-dilated with a safety margin of 2.0–2.5 mm longer balloon to reduce geographic mismatch. However, treatment with DEB+BMS showed more late lumen loss (P = 0.034) and less net luminal gain (P = 0.064) compared to EES after 6-month angiographic follow up. A study by Zurakowski et al [31] selected DEB 3–4 mm longer than the BMS to avoid geographical mismatch, and MACEs, TLR, and LLL were comparable between the
DEB+BMS and PES groups. Overall, geographical mismatch may be associated with negative outcomes of DEB+BMS, but do not constitute the main reason.

This meta-analysis presents a number of limitations that cannot be ignored. First, the sequence of devices (DEB first versus BMS first) may cause heterogeneity although a previous study found it doesn’t affect treatment outcomes [46]. Second, MACE definitions varied among RCTs, and we used the definitions reported in each study. As for LLL, most trials defined it with in-segment LLL, while distal main branch LLL was used in the DEBIUT trial [33], and in-stent LLL was reported in two studies [21,31]. Third, different types of DEBs have become an important source of heterogeneity. Therefore, sensitivity analysis was conducted by comparing SeQuent Please +BMS to DES. Fourth, the various comparators may be another source of heterogeneity. In the BMS group, EPC stents were applied in two studies [23,28] while in the DES group, both first- and second-generation DES were adapted. To mitigate heterogeneity, sensitivity analysis was conducted by excluding EPC stent, analyzing PES or EES exclusively. Nonetheless, information regarding comparison between DEB+BMS and second-generation DES was limited. Fifth, patients with STEMI or bifurcation lesions were involved in the study. In addition, follow-up duration in these trials was too short, especially for late ST, and long term follow-up RCTs are needed. Therefore, ST results should be interpreted carefully based on such small sample size studies.

Conclusions
This meta-analysis showed that treatment with DEB appears to be effective in de novo coronary artery disease. In addition, DEB+ BMS was clearly superior to BMS and inferior to DES for the treatment of patients with de novo coronary artery disease. Hence, DES (especially new generation DES) should be recommended for patients with de novo CAD.

Supporting information
S1 File. PRISMA 2009 checklist.
(DOCX)

Author Contributions
Conceptualization: SZL.
Data curation: KYC FY.
Formal analysis: KYC FY FX MZ WW JD.
Funding acquisition: SZL.
Investigation: KYC FY FX MZ WW JD.
Methodology: SZL XTS.
Project administration: SZL XTS.
Resources: KYC FY FX MZ WW JD.
Software: XTS.
Supervision: DFZ SZL XTS.
Validation: SZL XTS KYC.
Writing – original draft: KYC.
Writing – review & editing: SZL DFZ.

References

1. Stone GW, Ellis SG, Cox DA, Hermiller J, O’Shaughnessy C, Mann JT, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3):221–231. doi:10.1056/NEJMoa032441 PMID: 14724301

2. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, et al. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009; 119(25):3198–3206. doi:10.1161/CIRCULATIONAHA.108.826479 PMID: 19528338

3. Betala JV, Langan III EM, LaBerge M. Drug-coated percutaneous balloon catheters. Crit Rev Biomed Eng. 2014; 42(3–4):193–212. PMID: 25597236

4. Rymer JA, Harrison RW, Dai D, Roe MT, Messenger JC, Anderson HV, et al. Trends in Bare-Metal Stent Use in the United States in Patients Aged ≥ 65 Years (from the CathPCI Registry). Am J Cardiol. 2016; 118(7):959–966. doi:10.1016/j.amjcard.2016.06.061 PMID: 27614853

5. Palmerini T, Biondi-ZoccaI G, Della Riva D, Stettler C, Sangiorgi D, D’Ascenzo F, et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet. 2012; 379(9824):1393–1402. doi:10.1016/S0140-6736(12)60324-9 PMID: 22445239

6. Palmerini T, Benedetto U, Biondi-ZoccaI G, Della Riva D, Bacchi-Reggiani L, Smits PC, et al. Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis. J Am Coll Cardiol. 2015; 65(23):2496–2507. doi:10.1016/j.jacc.2015.04.017 PMID: 26065988

7. Urban P, Meredith IT, Abizaid A, Pocock SJ, Carrie D, Naber C, et al. Polymer-Free Drug-Coated Coronary Stents in Patients at High Bleeding Risk. N Engl J Med. 2015; 373(21):2038–2047. doi:10.1056/NEJMoa1503943 PMID: 26466021

8. Valgimigli M, PatiIaIakas A, Thury A, McFadden E, Colangelo S, Campo G, et al. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015; 65(8):805–815. doi:10.1016/j.jacc.2014.11.053 PMID: 25720624

9. Schnorr B, Speck U, Scheller B. Review of clinical data with Paccocath-coated balloon catheters. Minerva Cardioangiolog. 2011; 59(5):431–445. PMID: 21983304

10. Rittger H, Brachmann J, Sinha AM, Waliszewski M, Ohlow M, Brugger A, et al. A randomized, multicenter, single-blinded trial comparing paclitaxel-coated balloon angioplasty with plain balloon angioplasty in drug-eluting stent restenosis: the PEPCAD-DES study. J Am Coll Cardiol. 2012; 59(15):1377–1382. doi:10.1016/j.jacc.2012.01.015 PMID: 22386286

11. Byrne RA, Neumann FJ, Mehilli J, Pinieck S, Wolff B, Tiroch K, et al. Paclitaxel-eluting balloons, paclitaxel-eluting stents, and balloon angioplasty in patients with restenosis after implantation of a drug-eluting stent (ISAR-DESIRE 3): a randomised, open-label trial. Lancet. 2013; 381(9865):461–467. doi:10.1016/S0140-6736(12)61964-3 PMID: 23206837

12. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37):2541–2619. doi:10.1093/eurheartj/ehu278 PMID: 25173339

13. Frohlich GM, Lansky AJ, Ko DT, Archangelidi O, De Palma R, Timmis A, et al. Drug eluting balloons for de novo coronary lesions—a systematic review and meta-analysis. BMC Med. 2013; 11:123. doi:10.1186/1741-7015-11-123 PMID: 23657123

14. Zhang T, Sun S, Shen L, He B. Drug-eluting balloons for de novo coronary artery disease: a meta-analysis of angiographic and clinical data. Catheter Cardiovasc Interv. 2013; 82(7):1021–1030. doi:10.1002/ccd.23022 PMID: 23703742

15. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. doi:10.1371/journal.pmed.1000097 PMID: 19621072

16. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007; 115(17):2344–2351. doi:10.1161/CIRCULATIONAHA.106.685313 PMID: 17470709

17. Lundh A, Gotzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol. 2008; 8:22. doi:10.1186/1471-2288-8-22 PMID: 18426565
18. Ali RM, Degenhardt R, Zambahari R, Tresukosol D, Ahmad WA, Kamar H, et al. Paclitaxel-eluting balloon angioplasty and cobalt-chromium stents versus conventional angioplasty and paclitaxel-eluting stents in the treatment of native coronary artery stenoses in patients with diabetes mellitus. EuroIntervention. 2011; 7 Suppl K:K83–K92.

19. Belkacemi A, Agostoni P, Dubois C, Denis J, Naber C, Nathoe H, et al. 6-month angiographic and 18-month clinical results of the multicenter randomized DEBIUT (Drug Eluting Balloon in Bifurcations Trial). J Am Coll Cardiol. 2011; 58(20):B6.

20. Belkacemi A, Agostoni P, Nathoe HM, Voskuil M, Shao C, Van Belle E, et al. First results of the DEB-AMI (drug eluting balloon in acute ST-segment elevation myocardial infarction) trial: a multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in primary percutaneous coronary intervention with 6-month angiographic, intravascular, functional, and clinical outcomes. J Am Coll Cardiol. 2012; 59(25):2327–2337. https://doi.org/10.1016/j.jacc.2012.02.027 PMID: 22503057

21. Besic KM, Strozzi M, Marletic E, Bulem J, Kolaric B. Drug-eluting balloons in patients with non-ST elevation acute coronary syndrome. J Cardiol. 2015; 65(9):203–207. https://doi.org/10.1016/j.jhj.2015.05.007 PMID: 24976525

22. Buzza J, Brancati MF, Trani C, Pirozzolo G, De Maria G, Leone AM, et al. Impact of drug-eluting balloon (pre- or post-) dilation on neointima formation in de novo lesions treated by bare-metal stent: the IN-PACT CORO trial. Heart Vessels. 2016; 31(5):677–686. https://doi.org/10.1007/s00380-015-0671-3 PMID: 25863804

23. Camaro C, Jaspers Focks J, Brouwer M, Ten Cate T, Van Wely M, Gehlmann H, et al. Paclitaxel-eluting balloon versus conventional balloon predilatation in acute myocardial infarction undergoing endothelial progenitor cell-capture stent implantation: the DEBORA 2 randomised multicentre trial. EuroIntervention. 2015.

24. Hamm CW, Cremers B, Moellmann H, Möbius-Winkler S, Zeymer U, Vrolix M, et al. PEPCAD III: A randomised trial comparing a paclitaxel-coated balloon/stent system with a sirolimus eluting stent. Circulation. 2009; 120(21):2157.

25. Liistro F, Porto I, Angioli P, Grotti S, Ducci K, Falsini G, et al. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial. Am Heart J. 2013; 166(5):920–926. https://doi.org/10.1016/j.ahj.2013.08.023 PMID: 24176449

26. Lopez M, Nogales AJM, Doncel V, Sandoval J, Romany S, Martinez RP, et al. A prospective randomised study of the paclitaxel-coated balloon catheter in bifurcated coronary lesions (BABLION trial): 24-month clinical and angiographic results. EuroIntervention. 2014; 10(1):50–57. https://doi.org/10.4244/EIJV10I1A10 PMID: 24832638

27. Poerner TC, Otto S, Gassdorf J, Nitsche K, Janiak F, Scheller B, et al. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up. Circ Cardiovasc Interv. 2014; 7(6):760–767. https://doi.org/10.1161/CIRCINTERVENTIONS.113.001146 PMID: 25371536

28. Seeger J, Markovic S, Birkenmeyer R, Rittger H, Jung W, Brachmann J, et al. Paclitaxel-coated balloon plus bare-metal stent for de-novo coronary artery disease: final 5-year results of a randomized prospective multicenter trial. Coron Artery Dis. 2016; 27(2):84–88. https://doi.org/10.1097/MCA.0000000000000314 PMID: 26479698

29. Touchard AG, Goicolea J, Sabate M, Afonso F, Ruiz-Salmeron R, Bethencourt A, et al. Paclitaxel eluting balloon after bare metal STENT in ST elevation myocardial infarction (the PEBSI study). J Am Coll Cardiol. 2015; 65(10):A1708.

30. Yoon CH, Suh JW, Choi DJ, Chae IH. Comparison of drug-eluting balloon first and then bare metal stent with drug-eluting stent for treatment of de novo lesions (DEB First): A randomized controlled single center clinical trial. J Am Coll Cardiol. 2015; 65(17):S32–S33.

31. Zurakowski A, Buszman PP, Milewski KP, Janas A, Gorycki B, Kondys M, et al. Stenting and Adjunctive Delivery of Paclitaxel Via Balloon Coating Versus Durable Polymeric Matrix for De Novo Coronary Lesions: Clinical and Angiographic Results from the Prospective Randomized Trial. J Interv Cardiol. 2015; 28(4):348–357. https://doi.org/10.1111/joc.12210 PMID: 26224390

32. Poerner TC, Otto S, Gassdorf J, Nitsche K, Fuglia HR. Long-term clinical outcomes after combined drug-coated balloon/bare metal stent angioplasty compared with everolimus-eluting stents. Eur Heart J. 2015; 36:652–653.

33. Stella PR, Belkacemi A, Dubois C, Nathoe H, Denn J, Naber C, et al. A multicenter randomized comparison of drug-eluting balloon plus bare-metal stent versus bare-metal stent versus drug-eluting stent in bifurcation lesions treated with a single-stenting technique: six-month angiographic and 12-month
34. Fischer D, Scheller B, Schafer A, Klein G, Bohm M, Clever Y, et al. Paclitaxel-coated balloon plus bare metal stent vs. sirolimus-eluting stent in de novo lesions: an IVUS study. EuroIntervention. 2012; 8(4):450–455. https://doi.org/10.4244/EIJV8i4A71 PMID: 22917728

35. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol. 2007; 27(7):1500–1510. https://doi.org/10.1161/ATVBAHA.107.144220 PMID: 17510464

36. De Labroille A, Pakala R, Bonello L, Lemesle G, Scheinowitz M, Waksman R. Paclitaxel-eluting balloon: from bench to bed. Catheter Cardiovasc Interv. 2009; 73(5):643–52. https://doi.org/10.1002/ccd.21895 PMID: 19309715

37. Loh JP, Waksman R. Paclitaxel drug-coated balloons: a review of current status and emerging applications in native coronary artery de novo lesions. JACC Cardiovasc Interv. 2012; 5(10):1001–1012. https://doi.org/10.1016/j.jcin.2012.08.005 PMID: 23078727

38. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation. 2004; 110(7):810–814. https://doi.org/10.1161/01.CIR.0000138929.71660.E0 PMID: 15302790

39. Dangas GD, Serruys PW, Kereiakes DJ, Hermiller J, Rizvi A, Newman W, et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2013; 6(9):914–922. https://doi.org/10.1016/j.jcin.2013.05.005 PMID: 24058059

40. Liu Y, Gao L, Song Y, Chen L, Xue Q, Tian J, et al. Efficacy and safety of limus-eluting versus paclitaxel-eluting coronary artery stents in patients with diabetes mellitus: A meta-analysis. Int J Cardiol. 2015; 184:680–691. https://doi.org/10.1016/j.ijcard.2015.02.002 PMID: 25777069

41. Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010; 362(18):1663–1674. https://doi.org/10.1056/NEJMoa0910496 PMID: 20445180

42. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013; 347:f6625. https://doi.org/10.1136/bmj.f6625 PMID: 24212107

43. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: a systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014; 35(17):1147–1158. https://doi.org/10.1093/eurheartj/ehu570 PMID: 24459196

44. Cremers B, Biedermann M, Mahnkopf D, Bohm M, Scheller B. Comparison of two different paclitaxel-coated balloon catheters in the porcine coronary restenosis model. Clin Res Cardiol. 2008; 98(5):325–330. https://doi.org/10.1007/s00392-009-0008-2 PMID: 19280084

45. Unverdorben M, Kleber FX, Heuer H, Figulla HR, Vallbracht C, Leschke M, et al. Treatment of small coronary arteries with a paclitaxel-coated balloon catheter in the PEPCAD I study: are lesions clinically stable from 12 to 36 months? EuroIntervention. 2013; 9(5):620–628. https://doi.org/10.4244/EIJV9i5A99 PMID: 24058078

46. Gutierrez-Chico JL, van Geuns RJ, Koch KT, Koolen JJ, Duckers H, Regar E, et al. Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. EuroIntervention. 2011; 7(6):711–722. https://doi.org/10.4244/EIJV7i6A114 PMID: 21986329